![](https://endpts.com/wp-content/uploads/2024/01/Takeda-shutterstock-social1.jpg)
Takeda’s Ovid-licensed drug fails two Phase 3 epilepsy studies
Takeda’s enzyme therapy soticlestat, which aims to balance brain cholesterol and reduce seizures, failed two Phase 3 trials in certain forms … Sign up to read this article for free. Get free access to a limited number of articles, plus choose …